SCHEMBL2376665

SCHEMBL2376665

O=C1N(Cc2ccccc2)C(SCc2ccccc2)=NC12CC(c1ccccc1)Oc1ccc(Br)cc12

nearest known ligand 0.36

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 5/20 0.36
AKR1B1 P15121 2/20 0.36
TP53 P04637 3/20 0.35
MAPT P10636 2/20 0.35
SCN9A Q15858 1/20 0.35
PTPN1 P18031 2/20 0.35
KCNH2 Q12809 1/20 0.35
DRD2 P14416 1/20 0.33
DRD3 P35462 1/20 0.33
LMNA P02545 1/20 0.33
ALDH1A1 P00352 2/20 0.33
ALDH2 P05091 1/20 0.33
ALDH3A1 P30838 1/20 0.33
CNR1 P21554 1/20 0.32
CTSD P07339 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2376874 0.87 BACE1 (0.42) BACE1AKR1B1TP53MAPTSCN9A
SCHEMBL1828658 0.85 AKR1B1 (0.38) BACE1AKR1B1KCNH2LMNAALDH1A1
SCHEMBL12245589 0.82 AKR1B1 (0.37) BACE1AKR1B1TP53MAPTKCNH2
SCHEMBL2376310 0.82 AKR1B1 (0.37) BACE1AKR1B1TP53MAPTKCNH2
SCHEMBL2377903 0.82 AKR1B1 (0.37) BACE1AKR1B1TP53MAPTKCNH2
SCHEMBL7958932 0.82 SCN9A (0.39) BACE1AKR1B1SCN9AKCNH2
SCHEMBL2376466 0.82 BACE1 (0.47) BACE1AKR1B1KCNH2CTSD
SCHEMBL2376958 0.81 SCN9A (0.37) BACE1AKR1B1SCN9ACTSD
SCHEMBL12246268 0.81 BACE1 (0.41) BACE1AKR1B1KCNH2CTSD
SCHEMBL2376968 0.79 BACE1 (0.45) BACE1AKR1B1KCNH2CTSD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8921359-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2014-12-30 US disclosed
US-8921359-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2014-12-30 US disclosed
US-8921359-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2014-12-30 US disclosed
EP-2324032-B1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS INC (US) 2014-10-01 EP disclosed
US-20130317014-A1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. 2013-11-28 US disclosed
US-8450308-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2013-05-28 US disclosed
US-8450308-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2013-05-28 US disclosed
US-8450308-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2013-05-28 US disclosed
US-20110218192-A1 Inhibitors Of Beta-Secretase VITAE PHARMACEUTICALS, INC. (US) 2011-09-08 US disclosed
US-20110218192-A1 Inhibitors Of Beta-Secretase VITAE PHARMACEUTICALS, INC. (US) 2011-09-08 US disclosed
US-20110218192-A1 Inhibitors Of Beta-Secretase VITAE PHARMACEUTICALS, INC. (US) 2011-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110218192-A1 Inhibitors Of Beta-Secretase BACE1, BACE2, APP BACE1 1/4885AKR1B1 2656/4885TP53 2765/4885
US-20130317014-A1 INHIBITORS OF BETA-SECRETASE BACE1, BACE2, APP BACE1 1/4885AKR1B1 2656/4885TP53 2765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.